Domestic drug makers skimping on R&D investment

Published: 2013-05-22 06:58:00

Updated: 2013-05-22 06:58:00

Despite their relatively large assets, the nation’s 50 Korean pharmaceutical companies spend considerably less on research and development (R&D), industry data showed recently.

Citing the data released by the Financial Supervisory Service (FSS), Yakup.com, a pharmaceutical information portal,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK